Gilead leans on CymaBay liver drug, Trodelvy readouts and long-active PrEP yet to come this year

Gilead Sciences notched “fine” sales for the first quarter but the biopharma promised more to come.

Gilead reported sales of $6.6 billion, a 5% increase year-over-year, prompting Mizhuo analysts to write that the quarter “generally looks fine” on Thursday afternoon.

Executives emphasized seladelpar, a rare liver disease candidate that was picked up in its $4.3 billion CymaBay acquisition and has an August FDA decision date, in its Q1 earnings call Thursday. The potential primary biliary cholangitis treatment also is expected to get a decision in Europe in the first quarter of 2025.

Lenacapavir for HIV pre-exposure prophylaxis (PrEP) was another promise as Gilead plans a Phase 3 study update later this year and a potential launch of the twice-yearly PrEP option as early as late 2025. Lenacapavir is already approved as HIV treatment Sunlenca.

Gilead also highlighted three upcoming ASCO conference readouts, two for Trodelvy in lung cancer…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks